IRadimed Corp (IRMD) stock
Close on Nov 11, 2026Market cap $1.11BP/E 46.3Yield –
IRadimed Corp grew revenue 11.0% to $89.34M over the twelve months to Sep 30, 2026. Operating income rose 16.1% to $28.86M, moving the operating margin from 30.9% to 32.3%. Free cash flow was $26.14M, up 77.2% from a year earlier. At the latest close the market valued the company at $1.11B, 46.3 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.11B
- P/E ratio
- 46.3
- Price to sales
- 12.39
- Price to book
- 10.40
- Dividend yield
- –
- Free cash flow yield
- 2.36%
Fundamentals
- Revenue
- $89.34M
- Net income
- $23.98M
- EPS, diluted
- $1.87
- Free cash flow
- $26.14M
- Book value per share
- $8.27
- Diluted shares
- 13M
Trading
- Next earnings
- Feb 9, 2027 (estimated, before the open)
- Previous close
- $86.72
- Open
- $86.38
- Day's range
- $84.99 – $87.07
- Volume
- 79,774
- Average volume (20 days)
- 129,534
- Index membership
- Russell 2000, Russell 3000 (since Nov 2019)
- Beta (5 years)
- 0.75
- 52-week range
- $76.35 – $107.90
- RSI (14 days)
- 52.3
- Volatility (1 year)
- 31.7%
- Relative volume
- 0.63×
- WACC
- 8.7%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IRMD | S&P 500 | Difference | IRMD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.0% | -2.4% | +1.4 pts | ||
| 3 months | -2.4% | -1.2% | −1.3 pts | ||
| Year to date | -10.4% | +12.3% | −22.7 pts | ||
| 1 year | +3.7% | +12.4% | −8.7 pts | ||
| 3 years | +129.1% | +78.8% | +50.3 pts | +31.8% | +21.4% |
| 5 years | +148.1% | +75.2% | +73.0 pts | +19.9% | +11.9% |
| 10 years | +863.0% | +311.1% | +551.9 pts | +25.4% | +15.2% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases IRadimed filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- News
About IRadimed
Surgical & Medical Instruments & Apparatus
IRADIMED CORPORATION develops, manufactures, and sells medical devices, disposables, and services engineered for magnetic resonance imaging environments. Its core offerings include the MRidium 3870 and MRidium 3860+ non-magnetic intravenous infusion pump systems, proprietary single-use intravenous tubing sets, and the IRadimed 3880 patient vital signs monitoring system. The company also supplies ferromagnetic detection devices, replacement accessories, and maintenance contracts. Its products serve hospitals and acute care facilities worldwide, particularly radiology departments, intensive care units, emergency rooms, and surgical centers requiring continuous medication delivery and patient monitoring during scans.
Company profile, executives and historyIRadimed stock: common questions
What is IRadimed's stock price?
IRMD closed at $86.58 on Nov 11, 2026, down 0.16% on the day. Over the past 52 weeks it traded between $76.35 and $107.90.
What is IRadimed's market cap?
IRadimed was worth $1.11B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IRMD's P/E ratio?
IRMD trades at 46.3 times earnings, based on diluted earnings per share of $1.87 over the twelve months to Sep 30, 2026.
How much revenue does IRadimed make?
IRadimed reported revenue of $89.34M for the twelve months to Sep 30, 2026, up 11.0% from a year earlier.
Does IRadimed pay a dividend?
No. IRadimed has not paid a cash dividend over the last twelve months.
When does IRadimed report earnings next?
IRadimed is expected to report Q4 FY2026 results on Feb 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IRMD stock performed over the past year?
Including dividends, IRMD returned +3.7% over the past year, against +12.4% for the S&P 500.
How many IRMD shares are sold short?
1M shares were sold short at the latest FINRA report, 7.15% of the float, or 5.1 days of average trading volume.
Who are IRadimed's competitors?
Companies most similar to IRadimed by business, industry and size include KRMD, LUNG, TELA, XTNT, UTMD.
See a number that looks wrong?